Active ingredient
Ranibizumab
11 finished FDA listings contain Ranibizumab as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- RANIBIZUMAB
- Dosage forms
- Injection, Solution
- Routes
- Intravitreal
- Manufacturers / labelers
- 6
- Strengths listed
- .3 mg/.05ml · .5 mg/.05ml · 10 mg/ml · 100 mg/ml · 6 mg/ml
- Brand names in FDA listings
- Byooviz, Cimerli, Lucentis, Nufymco, Susvimo
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 595060
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| BLA 125156 | GENENTECH | 2006-06-30 | 2 |
| BLA 761202 | SAMSUNG BIOEPIS CO LTD | 2021-09-17 | 2 |
| BLA 761197 | GENENTECH INC | 2021-10-22 | 1 |
| BLA 761165 | SANDOZ INC | 2022-08-02 | 4 |
| BLA 761473 | FORMYCON AG | 2025-12-18 | 2 |
Official labeling on DailyMed
- NUFYMCO (RANIBIZUMAB-LEYK) INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS USA INC.] · version 1 · 2026-06-11
- BYOOVIZ (RANIBIZUMAB-NUNA) INJECTION, SOLUTION [HARROW EYE, LLC] · version 1 · 2026-01-02
- SUSVIMO (RANIBIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.] · version 14 · 2025-12-04
- BYOOVIZ (RANIBIZUMAB-NUNA) INJECTION, SOLUTION [BIOGEN INC.] · version 14 · 2025-12-02
- LUCENTIS (RANIBIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.] · version 27 · 2025-11-26
- CIMERLI (RANIBIZUMAB-EQRN) INJECTION, SOLUTION [SANDOZ INC] · version 3 · 2025-08-18
- CIMERLI (RANIBIZUMAB-EQRN) INJECTION, SOLUTION [COHERUS BIOSCIENCES INC] · version 12 · 2025-05-09
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.